Two Minnesota bio-science companies, The Integra Group of Brooklyn Park and Nanocopoeia of St. Paul, team in a global effort to speed the path to
market for advances in cardiovascular medicine
BROOKLYN PARK, Minn. and SAN DIEGO, June 17 /PRNewswire/ -- Coinciding with the BIO International Convention held in San Diego CA, NanoInterventions introduces the "Mouse Stent Model" for rapid screening of new coronary stent therapeutics. The model, complete with a mini-stent of spectacularly small size and its ability to replicate the human diseased vessel, represents a new starting point in the development of next-generation drug-eluting coronary stents. The company, NanoInterventions, emerged from the strategic global partnership of Minnesota-based The Integra Group of Brooklyn Park and Nanocopoeia of St. Paul, along with Stentome, with operations in Palo Alto CA, Galway, Ireland and Oxford, UK, and the University of Western Ontario, in London ON.
The Twin Cities is already home to two of the three largest stent
manufacturers and one of the largest clusters of medical device companies
in the world. With its local headquarters and base of operations, combined
with its global network of partners, NanoInterventions is ideally
positioned to speed the development of these life saving devices. The new
starting point for testing new stent-delivered therapies brings the
customer many novel benefits, including: establishing efficacy much earlier
in the process, speeding development-the experimental model requires 28 day
cycle versus a 180 day average cycle-and exploring molecular mechanisms of
action in the setting of a stented, diseased vessel. NanoInterventions'
managing partner, Robert A. Hoerr, MD, PhD, who is Nanocopoeia's CEO,
stated, "Our position within the heart of Minnesota's world-class medical
device community enabled us to build strategic relationships with the
talent and technology needed to launch this new development pathway for
Copyright©2008 PR Newswire.
All rights reserved